Statera Biopharma, Inc. announced the resignation of Peter Aronstam as Chief Financial Officer, effective from May 27, 2022. The Board of Directors of the Company has commenced a search for a new Chief Financial Officer.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0006 USD | 0.00% | 0.00% | 0.00% |
2023 | Statera Biopharma, Inc. entered into a letter of intent to acquire Worksite Labs. | CI |
2023 | Statera Biopharma, Inc.(OTCPK:STAB) dropped from S&P TMI Index | CI |
1st Jan change | Capi. | |
---|---|---|
0.00% | 43.55K | |
+34.01% | 51.07B | |
+34.66% | 38.61B | |
-8.02% | 38.78B | |
-8.98% | 27.32B | |
+12.56% | 26.35B | |
-19.62% | 19.46B | |
+39.18% | 13.58B | |
+31.47% | 12.46B | |
-3.40% | 11.75B |
- Stock Market
- Equities
- STAB Stock
- News Statera Biopharma, Inc.
- Statera Biopharma, Inc. Announces Resignation of Peter Aronstam as Chief Financial Officer